Lineage’s exclusive option and license agreement (the “Agreement”) with Factor was announced in 2023. The novel hypoimmune iPSC line received by Lineage contains a set of specific edits selected in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback